1-[2-(oxan-4-yl)ethyl]-5-[4-(1H-1,2,4-triazol-5-yl)phenyl]-2H-pyrazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[2-(oxan-4-yl)ethyl]-5-[4-(1H-1,2,4-triazol-5-yl)phenyl]-2H-pyrazine
• 化学式: C₁₉H₂₃N₅O
• 分子量: 337.4
• InChiKey: XRSRKHKUDQCXRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  66.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] TREATMENT OF CANCER WITH TOR KINASE INHIBITORS<br/>[FR] TRAITEMENT DU CANCER AVEC DES INHIBITEURS DE KINASE TOR
  申请人：SIGNAL PHARM LLC

  公开号：WO2014062878A2

  公开（公告）日：2014-04-24

  Provided herein are methods for treating or preventing prostate cancer, comprising administering an effective amount of a TOR kinase inhibitor to a patient having prostate cancer.
• [EN] INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY<br/>[FR] INHIBITION DE LA PHOSPHORYLATION DE PRAS40, GSK3-BETA OU P70S6K1 EN TANT QUE MARQUEUR DE L'ACTIVITÉ INHIBITRICE DE LA KINASE TOR
  申请人：SIGNAL PHARM LLC

  公开号：WO2014066125A2

  公开（公告）日：2014-05-01

  Provided herein are methods for treating a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3B or p70S6Kl, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a cancer treatable by inhibition of phosphorylation of PRAS40, GSK3β or p70S6K1.